Redeye reiterates its positive stance towards Vicore following the announcement of first Covid-19 patient being dosed in its phase II trial. We currently regard the Covid-19 indication as a bonus in our Base case, with considerable scope for re-valuation if results are proven encouraging. We expect top-line results from the trial already later this year.